Receptors, Prostaglandin E, EP4 Subtype
"Receptors, Prostaglandin E, EP4 Subtype" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subtype of prostaglandin E receptors that specifically couples to GS ALPHA GTP-BINDING PROTEIN SUBUNITS and subsequently activates ADENYLATE CYCLASE. The receptor may also signal through the activation of PHOSPHATIDYLINOSITOL 3-KINASE.
MeSH Number(s)
D12.776.543.750.100.200.700.600.400
Concept/Terms
Receptors, Prostaglandin E, EP4 Subtype- Receptors, Prostaglandin E, EP4 Subtype
- Prostaglandin E Receptor 4
- Receptor, Prostaglandin EP4
- EP4 Receptor, Prostaglandin
- Prostaglandin EP4 Receptor
- Prostaglandin EP4 Receptors
- EP4 Receptors, Prostaglandin
- Receptors, Prostaglandin EP4
- Prostanoid Receptor EP4
- EP4, Prostanoid Receptor
- Receptor EP4, Prostanoid
- PGE Receptor, EP4 Subtype
- Prostaglandin E2 Receptor, EP4 Subtype
Below are MeSH descriptors whose meaning is more general than "Receptors, Prostaglandin E, EP4 Subtype".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Prostaglandin E, EP4 Subtype".
This graph shows the total number of publications written about "Receptors, Prostaglandin E, EP4 Subtype" by people in Harvard Catalyst Profiles by year, and whether "Receptors, Prostaglandin E, EP4 Subtype" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2010 | 2 | 0 | 2 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 0 | 2 |
| 2015 | 2 | 1 | 3 |
| 2017 | 1 | 1 | 2 |
| 2018 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 0 | 2 |
| 2023 | 0 | 1 | 1 |
Below are the most recent publications written about "Receptors, Prostaglandin E, EP4 Subtype" by people in Profiles.
-
Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors. Cancer Res Commun. 2023 08; 3(8):1486-1500.
-
Eicosanoid regulation of debris-stimulated metastasis. Proc Natl Acad Sci U S A. 2021 10 12; 118(41).
-
Combination of EP4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells. Oncoimmunology. 2021 03 18; 10(1):1896643.
-
Whole-genome sequencing of African Americans implicates differential genetic architecture in inflammatory bowel disease. Am J Hum Genet. 2021 03 04; 108(3):431-445.
-
Inhibition of HIF-1a/EP4 axis by hyaluronate-trimethyl chitosan-SPION nanoparticles markedly suppresses the growth and development of cancer cells. Int J Biol Macromol. 2021 Jan 15; 167:1006-1019.
-
Prostanoid Receptors of the EP4-Subtype Mediate Gene Expression Changes in Human Airway Epithelial Cells with Potential Anti-Inflammatory Activity. J Pharmacol Exp Ther. 2021 02; 376(2):161-180.
-
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers. J Immunother Cancer. 2020 06; 8(1).
-
Ligand binding to human prostaglandin E receptor EP4 at the lipid-bilayer interface. Nat Chem Biol. 2019 01; 15(1):18-26.
-
Cellular density-dependent increases in HIF-1a compete with c-Myc to down-regulate human EP4 receptor promoter activity through Sp-1-binding region. Pharmacol Res Perspect. 2018 12; 6(6):e00441.
-
PGE2 production at sites of tissue injury promotes an anti-inflammatory neutrophil phenotype and determines the outcome of inflammation resolution in vivo. Sci Adv. 2018 09; 4(9):eaar8320.